Author Topic: (AAN abstract) Can immunomodulatory treatment be stopped in SPMS?  (Read 86 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
Presented at the annual AAN conference in Vancouver, BC, April 2016:

Quote

S24.002 - Can we stop immunomodulatory treatment in secondary progressive MS?

 April 18, 2016, 3:45 PM - 4:00 PM   

Authors

Julien Bonenfant,1 Veronique Deburghgraeve,2 Emmanuelle Le Page,1 Gilles Edan,3 Anne Kerbrat,2 Bajeux Emma1

1Rennes, France, 2, 3Cedex, France

Disclosures

 J. Bonenfant: None. V. Deburghgraeve: ; received compensation as a consultant with Bayer, Biogen-Idec ,Teva ,Novartis, Genzyme. E. Le Page: ; received compensation as a consultant with Bayer, Biogen-Idec ,Teva ,Novartis, Genzyme, No, No, No, No, No. G. Edan: ; Gilles Edan has received compensation as a consultant with Bayer, Biogen-Idec ,Teva ,Novartis, LFB.. A. Kerbrat: None. B. Emma: None.

Objective:

1) To describe the clinical and radiological outcome in SPMS patients after immunomodulatory treatment discontinuation

2) To identify factors associated with relapses and/or MRI activity of the disease after treatment discontinuation.

Background:

In secondary progressive MS (SPMS), immunomodulatory treatment [has] not shown significant effect on disability progression. [Whether or not to continue these costly treatments has] become a common issue in clinical practice for patients who have reached [the] secondary progressive phase. However, the impact of treatment discontinuation on relapse rate remains unknown.

Methods:

SPMS patients included in the EDMUS database of Rennes University hospital (France) were retrospectively selected.

Patients had 1) to be treated at least 6 months with an immunomodulatory treatment (interferonβ or glatiramer acetate), 2) to have stopped the treatment without [planning to switch], 3) to be followed at least 1 year after treatment discontinuation.

Clinical data (relapses, EDSS) and radiological data (restricted to gadolinium-enhancing lesions) before and after treatment discontinuation were assessed. Factors associated with relapses and/or MRI activity were identified using multivariate Cox proportional hazard model.

Results:

106 SPMS patients were included. The mean treatment duration was 5.0 ± 3.1 years. The mean follow up after treatment discontinuation was 5.2 ± 3.2 years. Seventeen patients experienced a relapse after discontinuation and 37 had clinical and/or radiological activity. The annual relapse rate remained stable at 1 year (0.09) and 3 years (0.07) after treatment discontinuation compared to 3 years (0.13) before discontinuation. Radiological activity in the 3 previous years and an EDSS < 6 were associated with [an] inflammatory event after discontinuation (p=0.03 and p=0.05 respectively). Treatment was finally resumed in 30 patients.

Conclusions:

Treatment discontinuation in SPMS patients was not associated with an increase in annualized relapse rate compared to [the rate for those on treatment].
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
68 Views
Last post March 12, 2019, 06:19:34 am
by agate
3 Replies
204 Views
Last post September 03, 2020, 08:32:19 pm
by agate
0 Replies
24 Views
Last post December 31, 2020, 03:51:14 pm
by agate
0 Replies
12 Views
Last post April 29, 2023, 09:29:43 pm
by agate
0 Replies
14 Views
Last post October 16, 2023, 09:21:58 pm
by agate